End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
7.43
CNY
|
-1.07%
|
|
+1.09%
|
-7.12%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
49,882
|
45,972
|
42,737
|
53,164
|
49,072
|
-
|
-
|
Enterprise Value (EV)
1 |
49,882
|
45,972
|
42,737
|
53,164
|
49,072
|
49,072
|
49,072
|
P/E ratio
|
35.2
x
|
35.9
x
|
22.6
x
|
29.6
x
|
23.2
x
|
20.1
x
|
17.9
x
|
Yield
|
-
|
-
|
-
|
0.38%
|
0.4%
|
0.4%
|
0.4%
|
Capitalization / Revenue
|
-
|
-
|
-
|
6.68
x
|
5.71
x
|
5.15
x
|
4.67
x
|
EV / Revenue
|
-
|
-
|
-
|
6.68
x
|
5.71
x
|
5.15
x
|
4.67
x
|
EV / EBITDA
|
-
|
-
|
-
|
22.2
x
|
18.6
x
|
16.8
x
|
14.9
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
1.79
x
|
1.56
x
|
1.44
x
|
1.34
x
|
Nbr of stocks (in thousands)
|
6,740,788
|
6,740,788
|
6,740,788
|
6,645,481
|
6,604,635
|
-
|
-
|
Reference price
2 |
7.400
|
6.820
|
6.340
|
8.000
|
7.430
|
7.430
|
7.430
|
Announcement Date
|
4/22/21
|
4/27/22
|
4/24/23
|
4/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
7,964
|
8,601
|
9,524
|
10,517
|
EBITDA
1 |
-
|
-
|
-
|
2,395
|
2,644
|
2,923
|
3,283
|
EBIT
1 |
-
|
-
|
-
|
2,225
|
2,728
|
3,139
|
3,617
|
Operating Margin
|
-
|
-
|
-
|
27.94%
|
31.72%
|
32.96%
|
34.39%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
2,204
|
2,714
|
3,125
|
3,603
|
Net income
1 |
1,324
|
1,295
|
1,880
|
1,779
|
2,101
|
2,447
|
2,760
|
Net margin
|
-
|
-
|
-
|
22.34%
|
24.43%
|
25.69%
|
26.25%
|
EPS
2 |
0.2100
|
0.1900
|
0.2800
|
0.2700
|
0.3200
|
0.3700
|
0.4150
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
0.0300
|
0.0300
|
0.0300
|
0.0300
|
Announcement Date
|
4/22/21
|
4/27/22
|
4/24/23
|
4/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
2,029
|
2,056
|
2,038
|
2,257
|
2,250
|
2,451
|
2,183
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
548.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.0820
|
-
|
0.1140
|
0.0800
|
0.1000
|
0.0500
|
0.1000
|
0.0900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/24/23
|
4/28/24
|
4/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
6.06%
|
6.9%
|
7.24%
|
7.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
6.4%
|
6.6%
|
6.7%
|
Assets
1 |
-
|
-
|
-
|
-
|
32,828
|
37,078
|
41,196
|
Book Value Per Share
2 |
-
|
-
|
-
|
4.460
|
4.750
|
5.150
|
5.570
|
Cash Flow per Share
2 |
-
|
-
|
-
|
0.3400
|
-0.0400
|
0.4500
|
0.0400
|
Capex
1 |
-
|
-
|
-
|
448
|
40
|
20
|
10
|
Capex / Sales
|
-
|
-
|
-
|
5.63%
|
0.47%
|
0.21%
|
0.1%
|
Announcement Date
|
4/22/21
|
4/27/22
|
4/24/23
|
4/28/24
|
-
|
-
|
-
|
Last Close Price
7.43
CNY Average target price
6
CNY Spread / Average Target -19.25% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.12% | 6.86B | | -1.26% | 89.46B | | +2.76% | 40.74B | | -8.89% | 33.03B | | +55.32% | 24.68B | | -16.36% | 15.12B | | -8.98% | 12.81B | | -12.11% | 11.79B | | -43.61% | 11.64B | | +7.79% | 8.9B |
Biopharmaceuticals
|